↓ Skip to main content

Data exclusivity exceptions and compulsory licensing to promote generic medicines in the European Union: A proposal for greater coherence in European pharmaceutical legislation

Overview of attention for article published in Journal of Pharmaceutical Policy and Practice, June 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#7 of 193)
  • High Attention Score compared to outputs of the same age (92nd percentile)

Mentioned by

policy
2 policy sources
twitter
29 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
43 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Data exclusivity exceptions and compulsory licensing to promote generic medicines in the European Union: A proposal for greater coherence in European pharmaceutical legislation
Published in
Journal of Pharmaceutical Policy and Practice, June 2017
DOI 10.1186/s40545-017-0107-9
Pubmed ID
Authors

Ellen F. M. ‘t Hoen, Pascale Boulet, Brook K. Baker

Abstract

The challenge of providing access to high-priced patented medicines is a global problem affecting all countries. A decade and a half ago the use of flexibilities contained in the World Trade Organization Agreement on Trade Related Aspects of Intellectual Property Rights, in particular compulsory licensing, was seen as a mechanism to respond to high-price medicines for the treatment of HIV/AIDS in low- and middle-income countries. Today a number of upper-income European Union (EU) Member States are contemplating the use of compulsory licensing in their efforts to reduce expenditure on pharmaceutical products. EU regulation of clinical test data protection and the granting of market exclusivity interfere with the effective use of compulsory licensing by EU Member States and can even prevent access to off-patent medicines because they prohibit registration of generic equivalents. EU pharmaceutical legislation should be amended to allow waivers to data and market exclusivity in cases of public health need and when a compulsory or government use license has been issued. Such an amendment can be modelled after existing waivers in the EU Regulation on compulsory licensing of patents for the manufacture of pharmaceutical products for export to countries with public health problems outside the EU. Allowing a public health/compulsory license exception to data and market exclusivity would bring greater coherence between EC regulation of medicinal products and national provisions on compulsory licensing and ensure that Member States can take measures to protect public health and promote access to medicines for all.

Twitter Demographics

The data shown below were collected from the profiles of 29 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 43 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 9 21%
Researcher 7 16%
Student > Ph. D. Student 5 12%
Student > Bachelor 5 12%
Other 3 7%
Other 6 14%
Unknown 8 19%
Readers by discipline Count As %
Social Sciences 8 19%
Pharmacology, Toxicology and Pharmaceutical Science 5 12%
Economics, Econometrics and Finance 4 9%
Biochemistry, Genetics and Molecular Biology 4 9%
Medicine and Dentistry 3 7%
Other 10 23%
Unknown 9 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 29. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 January 2019.
All research outputs
#647,896
of 14,559,097 outputs
Outputs from Journal of Pharmaceutical Policy and Practice
#7
of 193 outputs
Outputs of similar age
#20,998
of 265,420 outputs
Outputs of similar age from Journal of Pharmaceutical Policy and Practice
#1
of 1 outputs
Altmetric has tracked 14,559,097 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 193 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.5. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 265,420 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them